Dysregulated glycolysis as an oncogenic event

Cellular and Molecular Life Sciences

Volumn 72, Issue 10, 2015, Pages 1881-1892

  Mikawa, Takumi ^a   Lleonart, Matilde E ^b   Takaori Kondo, Akifumi ^a   Inagaki, Nobuya ^a   Yokode, Masayuki ^c   Kondoh, Hiroshi ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cancer; HIF 1; Myc; PGAM; Sirtuin; Warburg effect

Indexed keywords

BIOLOGICAL MODEL; CARCINOGENESIS; CELL HYPOXIA; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; UBIQUITINATION;

CARCINOGENESIS; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; NEOPLASMS; UBIQUITINATION;

EID: 84931835248     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-015-1840-3     Document Type: Article

References (146)

1. Tarui S (1995) Glycolytic defects in muscle: aspects of collaboration between basic science and clinical medicine. Muscle Nerve Suppl 3:S2-S9. doi: 10.1002/mus.880181404
2. Bouche C, Serdy S, Kahn CR, Goldfine AB (2004) The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25(5):807-830. doi: 10.1210/er.2003-0026
3. Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269-270
4. Durany N, Joseph J, Campo E, Molina R, Carreras J (1997) Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer 75(7):969-977
5. Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84(6):1014-1020. doi: 10.1016/j.ygeno.2004.08.010
6. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029-1033. doi: 10.1126/science.1160809
7. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656-670. doi: 10.1016/j.cell.2012.01.058
8. Hitosugi T, Zhou L, Elf S, Fan J, Kang HB, Seo JH, Shan C, Dai Q, Zhang L, Xie J, Gu TL, Jin P, Aleckovic M, Leroy G, Kang Y, Sudderth JA, Deberardinis RJ, Luan CH, Chen GZ, Muller S, Shin DM, Owonikoko TK, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Ye K, Boggon TJ, Kang S, He C, Chen J (2012) Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22(5):585-600. doi: 10.1016/j.ccr.2012.09.020
9. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D (2005) Glycolytic enzymes can modulate cellular life span. Cancer Res 65(1):177-185
10. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi: 10.1016/j.cell.2011.02.013
11. Gitenay D, Wiel C, Lallet-Daher H, Vindrieux D, Aubert S, Payen L, Simonnet H, Bernard D (2014) Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. Cell Death Dis 5:e1089. doi: 10.1038/cddis.2014.63
12. Onodera Y, Nam JM, Bissell MJ (2014) Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Investig 124(1):367-384. doi: 10.1172/JCI63146
13. Granchi C, Minutolo F (2012) Anticancer agents that counteract tumor glycolysis. ChemMedChem 7(8):1318-1350. doi: 10.1002/cmdc.201200176
14. Jang M, Kim SS, Lee J (2013) Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 45:e45. doi: 10.1038/emm.2013.85
15. Banaszak K, Mechin I, Obmolova G, Oldham M, Chang SH, Ruiz T, Radermacher M, Kopperschlager G, Rypniewski W (2011) The crystal structures of eukaryotic phosphofructokinases from baker's yeast and rabbit skeletal muscle. J Mol Biol 407(2):284-297. doi: 10.1016/j.jmb.2011.01.019
16. Hasawi NA, Khandari MA, Luqmani YA (2014) Phosphofructokinase: a mediator of glycolytic flux in cancer progression. Crit Rev Oncol Hematol. doi: 10.1016/j.critrevonc.2014.05.007
17. Prabhakar NR, Semenza GL (2012) Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92(3):967-1003. doi: 10.1152/physrev.00030.2011
18. Liang J, Mills GB (2013) AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73(10):2929-2935. doi: 10.1158/0008-5472.CAN-12-3876
19. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891-899. doi: 10.1038/nrc1478
20. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202(3):654-662. doi: 10.1002/jcp.20166
21. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(34):4777-4786. doi: 10.1038/sj.onc.1209603
22. Pedersen PL (2007) Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39(3):211-222. doi: 10.1007/s10863-007-9094-x
23. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19(1):17-24. doi: 10.1016/j.semcancer.2008.11.006
24. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF (2012) Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget 3(9):940-953
25. Li Z, Yang P, Li Z (2014) The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta 1846(2):285-296. doi: 10.1016/j.bbcan.2014.07.008
26. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG (2013) PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155(2):397-409. doi: 10.1016/j.cell.2013.09.025
27. Gao X, Wang H, Yang JJ, Liu X, Liu ZR (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45(5):598-609. doi: 10.1016/j.molcel.2012.01.001
28. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480(7375):118-122. doi: 10.1038/nature10598
29. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150(4):685-696. doi: 10.1016/j.cell.2012.07.018
30. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y, Lu Z (2014) PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell 53(1):75-87. doi: 10.1016/j.molcel.2013.11.001
31. Kwon OH, Kang TW, Kim JH, Kim M, Noh SM, Song KS, Yoo HS, Kim WH, Xie Z, Pocalyko D, Kim SY, Kim YS (2012) Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun 423(1):38-44. doi: 10.1016/j.bbrc.2012.05.063
32. Lee J, Kim HK, Han YM, Kim J (2008) Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 40(5):1043-1054. doi: 10.1016/j.biocel.2007.11.009
33. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145(5):732-744. doi: 10.1016/j.cell.2011.03.054
34. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593-602. doi: 10.1016/S0092-8674(00)81902-9
35. Chen Q, Ames BN (1994) Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 91(10):4130-4134
36. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J (2003) Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5(8):741-747. doi: 10.1038/ncb1024
37. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M (2005) Tumour biology: senescence in premalignant tumours. Nature 436(7051):642. doi: 10.1038/436642a
38. Kondoh H, Lleonart ME, Nakashima Y, Yokode M, Tanaka M, Bernard D, Gil J, Beach D (2007) A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal 9(3):293-299. doi: 10.1089/ars.2007.9.ft-14
39. Okuda J, Niizuma S, Shioi T, Kato T, Inuzuka Y, Kawashima T, Tamaki Y, Kawamoto A, Tanada Y, Iwanaga Y, Narazaki M, Matsuda T, Adachi S, Soga T, Takemura G, Kondoh H, Kita T, Kimura T (2013) Persistent overexpression of phosphoglycerate mutase, a glycolytic enzyme, modifies energy metabolism and reduces stress resistance of heart in mice. PLoS One 8(8):e72173. doi: 10.1371/journal.pone.0072173
40. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O (2011) Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem 80:825-858. doi: 10.1146/annurev-biochem-060608-102511
41. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3(2):177-182. doi: 10.1038/nm0297-177
42. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92(12):5510-5514
43. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, Keith B (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20(5):557-570. doi: 10.1101/gad.1399906
44. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281(22):15215-15226. doi: 10.1074/jbc.M511408200
45. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63(19):6130-6134
46. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149-162. doi: 10.1101/gad.12.2.149
47. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3(3):177-185. doi: 10.1016/j.cmet.2006.02.002
48. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3(3):187-197. doi: 10.1016/j.cmet.2006.01.012
49. Kennedy KM, Dewhirst MW (2010) Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 6(1):127-148. doi: 10.2217/fon.09.145
50. Maynard MA, Ohh M (2007) The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci CMLS 64(16):2170-2180. doi: 10.1007/s00018-007-7082-2
51. Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325-337. doi: 10.1038/nrc3038
52. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23(9):1949-1956. doi: 10.1038/sj.emboj.7600196
53. Gariboldi MB, Ravizza R, Monti E (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80(4):455-462. doi: 10.1016/j.bcp.2010.05.011
54. Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T, Gorlach A (2007) Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 18(12):4691-4697. doi: 10.1091/mbc.E07-04-0391
55. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G, Flamme I (2003) Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278(9):7520-7530. doi: 10.1074/jbc.M211298200
56. Le Bras A, Lionneton F, Mattot V, Lelievre E, Caetano B, Spruyt N, Soncin F (2007) HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 26(53):7480-7489. doi: 10.1038/sj.onc.1210566
57. Bingham C, Hattersley AT (2004) Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant Off Publication Eur Dial Transpl Assoc Eur Renal Assoc 19(11):2703-2708. doi: 10.1093/ndt/gfh348
58. Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, Baba T, Hamanishi J, Abiko K, Kosaka K, Murphy SK, Mori S, Konishi I (2013) Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog. doi: 10.1002/mc.22072
59. Itamochi H, Kigawa J, Terakawa N (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99(4):653-658. doi: 10.1111/j.1349-7006.2008.00747.x
60. Baba T, Otake H, Sato T, Miyabayashi K, Shishido Y, Wang CY, Shima Y, Kimura H, Yagi M, Ishihara Y, Hino S, Ogawa H, Nakao M, Yamazaki T, Kang D, Ohkawa Y, Suyama M, Chung BC, Morohashi K (2014) Glycolytic genes are targets of the nuclear receptor Ad4BP/SF-1. Nat Commun 5:3634. doi: 10.1038/ncomms4634
61. Discher DJ, Bishopric NH, Wu X, Peterson CA, Webster KA (1998) Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 273(40):26087-26093. doi: 10.1074/jbc.273.40.26087
62. Schafer D, Hamm-Kunzelmann B, Brand K (1997) Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1. FEBS Lett 417(3):325-328. doi: 10.1016/S0014-5793(97)01314-8
63. Panasyuk G, Espeillac C, Chauvin C, Pradelli LA, Horie Y, Suzuki A, Annicotte JS, Fajas L, Foretz M, Verdeguer F, Pontoglio M, Ferre P, Scoazec JY, Birnbaum MJ, Ricci JE, Pende M (2012) PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat Commun 3:672. doi: 10.1038/ncomms1667
64. Singh PK, Mehla K, Hollingsworth MA, Johnson KR (2011) Regulation of Aerobic Glycolysis by microRNAs in Cancer. Mol Cell Pharmacol 3(3):125-134
65. Yang F, Zhang H, Mei Y, Wu M (2014) Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell 53(1):88-100. doi: 10.1016/j.molcel.2013.11.004
66. Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2(2):103-112. doi: 10.1016/S1535-6108(02)00102-2
67. Feng Z, Levine AJ (2010) The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 20(7):427-434. doi: 10.1016/j.tcb.2010.03.004
68. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277(41):38205-38211. doi: 10.1074/jbc.M203781200
69. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39(2):171-183. doi: 10.1016/j.molcel.2010.06.022
70. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE (2003) Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278(17):14599-14602. doi: 10.1074/jbc.C300063200
71. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64(11):3892-3899. doi: 10.1158/0008-5472.CAN-03-2904
72. Ro TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Borset M (2013) HGF and IGF-1 synergize with SDF-1alpha in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp Hematol 41(7):646-655. doi: 10.1016/j.exphem.2013.03.002
73. Sun J, Khalid S, Rozakis-Adcock M, Fantus IG, Jin T (2009) P-21-activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine. Oncogene 28(35):3132-3144. doi: 10.1038/onc.2009.167
74. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R (2009) PAK signaling in oncogenesis. Oncogene 28(28):2545-2555. doi: 10.1038/onc.2009.119
75. Shalom-Barak T, Knaus UG (2002) A p21-activated kinase-controlled metabolic switch up-regulates phagocyte NADPH oxidase. J Biol Chem 277(43):40659-40665. doi: 10.1074/jbc.M206650200
76. Tunduguru R, Chiu TT, Ramalingam L, Elmendorf JS, Klip A, Thurmond DC (2014) Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells. Biochem Pharmacol. doi: 10.1016/j.bcp.2014.08.033
77. Cooper JA, Reiss NA, Schwartz RJ, Hunter T (1983) Three glycolytic enzymes are phosphorylated at tyrosine in cells transformed by Rous sarcoma virus. Nature 302(5905):218-223. doi: 10.1038/302218a0
78. Hitosugi T, Zhou L, Fan J, Elf S, Zhang L, Xie J, Wang Y, Gu TL, Aleckovic M, LeRoy G, Kang Y, Kang HB, Seo JH, Shan C, Jin P, Gong W, Lonial S, Arellano ML, Khoury HJ, Chen GZ, Shin DM, Khuri FR, Boggon TJ, Kang S, He C, Chen J (2013) Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun 4:1790. doi: 10.1038/ncomms2759
79. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science Signal 2(97):ra73. doi: 10.1126/scisignal.2000431
80. Yeung SJ, Pan J, Lee MH (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci CMLS 65(24):3981-3999. doi: 10.1007/s00018-008-8224-x
81. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94(13):6658-6663
82. Kawauchi K, Araki K, Tobiume K, Tanaka N (2008) p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10(5):611-618. doi: 10.1038/ncb1724
83. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275(29):21797-21800. doi: 10.1074/jbc.C000023200
84. Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV (2004) Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 24(13):5923-5936. doi: 10.1128/MCB.24.13.5923-5936.2004
85. David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463(7279):364-368. doi: 10.1038/nature08697
86. Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR (2010) The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci USA 107(5):1894-1899. doi: 10.1073/pnas.0914845107
87. Mathupala SP, Heese C, Pedersen PL (1997) Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272(36):22776-22780. doi: 10.1074/jbc.272.36.22776
88. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126(1):107-120. doi: 10.1016/j.cell.2006.05.036
89. Burns DM, Richter JD (2008) CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev 22(24):3449-3460. doi: 10.1101/gad.1697808
90. Ruiz-Lozano P, Hixon ML, Wagner MW, Flores AI, Ikawa S, Baldwin AS Jr, Chien KR, Gualberto A (1999) p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression. Cell Growth Differ 10(5):295-306
91. Mikawa T, Maruyama T, Okamoto K, Nakagama H, Lleonart ME, Tsusaka T, Hori K, Murakami I, Izumi T, Takaori-Kondo A, Yokode M, Peters G, Beach D, Kondoh H (2014) Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. J Cell Biol 204(5):729-745. doi: 10.1083/jcb.201306149
92. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479. doi: 10.1146/annurev.biochem.67.1.425
93. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296-299. doi: 10.1038/387296a0
94. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387(6630):299-303. doi: 10.1038/387299a0
95. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53(10 Suppl):2231-2234
96. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53(12):2736-2739
97. Brown DR, Thomas CA, Deb SP (1998) The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 17(9):2513-2525. doi: 10.1093/emboj/17.9.2513
98. Manfredi JJ (2010) The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 24(15):1580-1589. doi: 10.1101/gad.1941710
99. McCay CM, Crowell MF (1934) Prolonging the life span. Sci Mon 39(5):405-414
100. Canto C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20(2):98-105. doi: 10.1097/MOL.0b013e328328d0a4
101. Yecies JL, Manning BD (2011) mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 89(3):221-228. doi: 10.1007/s00109-011-0726-6
102. Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene 27(Suppl 2):S43-S51. doi: 10.1038/onc.2009.352
103. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Costoya JA, Senaris R (2013) AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res 73(8):2628-2638. doi: 10.1158/0008-5472.CAN-12-0861
104. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J, Asara J, McGraw TE, Kahn BB, Cantley LC (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 49(6):1167-1175. doi: 10.1016/j.molcel.2013.01.035
105. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18(3):283-293. doi: 10.1016/j.molcel.2005.03.027
106. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17(1):113-124. doi: 10.1016/j.cmet.2012.12.001
107. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403(6771):795-800. doi: 10.1038/35001622
108. Zwaans BM, Lombard DB (2014) Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis Models Mech 7(9):1023-1032. doi: 10.1242/dmm.016287
109. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, Deng CX (2011) SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20(4):487-499. doi: 10.1016/j.ccr.2011.09.004
110. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, Gius D (2010) SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17(1):41-52. doi: 10.1016/j.ccr.2009.11.023
111. Jeong SM, Lee A, Lee J, Haigis MC (2014) SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J Biol Chem 289(7):4135-4144. doi: 10.1074/jbc.M113.525949
112. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenson JK, MacDonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weissleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB, Mostoslavsky R (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151(6):1185-1199. doi: 10.1016/j.cell.2012.10.047
113. Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, Imai S (2013) Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab 18(3):416-430. doi: 10.1016/j.cmet.2013.07.013
114. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen HY (2012) The sirtuin SIRT6 regulates lifespan in male mice. Nature 483(7388):218-221. doi: 10.1038/nature10815
115. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL (2012) SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 19(6):2011-2019. doi: 10.1245/s10434-011-2159-4
116. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY (2009) Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 15(13):4453-4459. doi: 10.1158/1078-0432.CCR-08-3329
117. Noguchi A, Kikuchi K, Zheng H, Takahashi H, Miyagi Y, Aoki I, Takano Y (2014) SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med. doi: 10.1002/cam4.310
118. Yuan J, Minter-Dykhouse K, Lou Z (2009) A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 185(2):203-211. doi: 10.1083/jcb.200809167
119. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 38(6):864-878. doi: 10.1016/j.molcel.2010.05.023
120. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R (2010) The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140(2):280-293. doi: 10.1016/j.cell.2009.12.041
121. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish CB, Pandolfi PP, Haigis MC (2011) SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 19(3):416-428. doi: 10.1016/j.ccr.2011.02.014
122. Hubbi ME, Hu H, Kshitiz, Gilkes DM, Semenza GL (2013) Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J Biol Chem 288(29):20768-20775. doi: 10.1074/jbc.M113.476903
123. Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy AJ, Valenzuela DM, Luo H, Kapahi P, Krauss R, Mostoslavsky R, Yancopoulos GD, Alt FW, Chua KF, Chen D (2013) SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep 5(3):654-665. doi: 10.1016/j.celrep.2013.10.007
124. Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, Qian DZ (2011) HDAC4 protein regulates HIF1alpha protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem 286(44):38095-38102. doi: 10.1074/jbc.M111.257055
125. Zhao D, Zou SW, Liu Y, Zhou X, Mo Y, Wang P, Xu YH, Dong B, Xiong Y, Lei QY, Guan KL (2013) Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell 23(4):464-476. doi: 10.1016/j.ccr.2013.02.005
126. Tsusaka T, Guo T, Yagura T, Inoue T, Yokode M, Inagaki N, Kondoh H (2014) Deacetylation of phosphoglycerate mutase in its distinct central region by SIRT2 down-regulates its enzymatic activity. Genes Cells Devoted Mol Cell Mech 19(10):766-777. doi: 10.1111/gtc.12176
127. Xu Y, Li F, Lv L, Li T, Zhou X, Deng CX, Guan KL, Lei QY, Xiong Y (2014) Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res 74(13):3630-3642. doi: 10.1158/0008-5472.CAN-13-3615
128. Hallows WC, Yu W, Denu JM (2012) Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J Biol Chem 287(6):3850-3858. doi: 10.1074/jbc.M111.317404
129. Li T, Liu M, Feng X, Wang Z, Das I, Xu Y, Zhou X, Sun Y, Guan KL, Xiong Y, Lei QY (2014) Glyceraldehyde-3-phosphate dehydrogenase is activated by lysine 254 acetylation in response to glucose signal. J Biol Chem 289(6):3775-3785. doi: 10.1074/jbc.M113.531640
130. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, Lei QY (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42(6):719-730. doi: 10.1016/j.molcel.2011.04.025
131. Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, Lei QY, Xiong Y (2013) Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell 52(3):340-352. doi: 10.1016/j.molcel.2013.09.004
132. Kaelin WG Jr, Maher ER (1998) The VHL tumour-suppressor gene paradigm. Trends Genet TIG 14(10):423-426. doi: 10.1016/S0168-9525(98)01558-3
133. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97(19):10430-10435. doi: 10.1073/pnas.190332597
134. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271-275. doi: 10.1038/20459
135. Chan DA, Sutphin PD, Yen SE, Giaccia AJ (2005) Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25(15):6415-6426. doi: 10.1128/MCB.25.15.6415-6426.2005
136. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F (2004) JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118(6):781-794. doi: 10.1016/j.cell.2004.08.025
137. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, Olivier AK, Spitz DR, Gius D (2010) Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 40(6):893-904. doi: 10.1016/j.molcel.2010.12.013
138. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8(2):143-153. doi: 10.1016/j.ccr.2005.06.017
139. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7(1):77-85. doi: 10.1016/j.ccr.2004.11.022
140. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277(26):23111-23115. doi: 10.1074/jbc.M202487200
141. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1):17-30. doi: 10.1016/j.ccr.2010.12.014
142. Keller KE, Tan IS, Lee YS (2012) SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 338(6110):1069-1072. doi: 10.1126/science.1224409
143. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329(5998):1492-1499. doi: 10.1126/science.1188015
144. Musi N, Goodyear LJ (2003) AMP-activated protein kinase and muscle glucose uptake. Acta Physiol Scand 178(4):337-345. doi: 10.1046/j.1365-201X.2003.01168.x
145. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diabet Care 33(7):1674-1685. doi: 10.2337/dc10-0666
146. Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS (2011) Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One 6(11):e28068. doi: 10.1371/journal.pone.0028068